{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:10:54Z","timestamp":1786680654068,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1104704"],"award-info":[{"award-number":["2022YFA1104704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92059204"],"award-info":[{"award-number":["92059204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273419"],"award-info":[{"award-number":["82273419"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ymthe.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:57:30Z","timestamp":1730926650000},"page":"336-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis"],"prefix":"10.1016","volume":"33","author":[{"given":"Xuejia","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjie","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-1224","authenticated-orcid":false,"given":"Shicang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.11.010_bib1","first-page":"1","article-title":"Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective","volume":"14","author":"Kadamkulam Syriac","year":"2022","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"10.1016\/j.ymthe.2024.11.010_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The Evolving Landscape of Brain Metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2024.11.010_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib4","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib5","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2024.11.010_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12032-014-0400-2","article-title":"CNS metastases in breast cancer patients: prognostic implications of tumor subtype","volume":"32","author":"Bachmann","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib7","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2024.11.010_bib9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21037\/atm.2018.04.35","article-title":"Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies","volume":"6","author":"Brosnan","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/OTT.S293685","article-title":"Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets","volume":"14","author":"Lv","year":"2021","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.wneu.2011.03.048","article-title":"A review of brain abscess surgical treatment--78 years: aspiration versus excision","volume":"76","author":"Ratnaike","year":"2011","journal-title":"World Neurosurg."},{"key":"10.1016\/j.ymthe.2024.11.010_bib13","doi-asserted-by":"crossref","first-page":"e1557","DOI":"10.1016\/j.wneu.2018.11.100","article-title":"Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis","volume":"122","author":"Lamba","year":"2019","journal-title":"World Neurosurg."},{"key":"10.1016\/j.ymthe.2024.11.010_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936117","article-title":"Evolving treatment strategies of brain metastases from breast cancer: current status and future direction","volume":"12","author":"Kim","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2024.11.010_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.11.010_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036863","article-title":"New Approaches on Cancer Immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine Therapies for Cancer: Then and Now","volume":"16","author":"Morse","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.010_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on Immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib23","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib24","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-16-1327","article-title":"Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases","volume":"22","author":"Osswald","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CJI.0000000000000483","article-title":"Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models","volume":"46","author":"Yang","year":"2023","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2024.11.010_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10637-020-00937-y","article-title":"Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A","volume":"38","author":"Breen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymthe.2024.11.010_bib27","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","article-title":"Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib29","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abe359","article-title":"Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer","volume":"16","author":"Correa","year":"2021","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.ymthe.2024.11.010_bib30","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.18632\/oncotarget.27778","article-title":"Heterogeneity of CEACAM5 in breast cancer","volume":"11","author":"Bechmann","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2024.11.010_bib31","doi-asserted-by":"crossref","first-page":"11054","DOI":"10.18632\/aging.102510","article-title":"EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.ymthe.2024.11.010_bib32","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.18632\/oncotarget.4461","article-title":"Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types","volume":"6","author":"Lamberts","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2024.11.010_bib33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib34","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Alewine","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2024.11.010_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051357","article-title":"Challenges of Anti-Mesothelin CAR-T-Cell Therapy","volume":"15","author":"Zhai","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.11.010_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2019.11.012","article-title":"Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in\u00a0vivo histidine (1)H-MR spectroscopy study","volume":"87","author":"Lyros","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2024.11.010_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10555-019-09787-4","article-title":"Acidosis and cancer: from mechanism to neutralization","volume":"38","author":"Ibrahim-Hashim","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2024.11.010_bib39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0014-4886(74)90029-6","article-title":"Effect of intravenous NH4Cl and NaHCO3 on the pH of the brain surface, as related to respiration and the blood-brain barrier","volume":"42","author":"Rapoport","year":"1974","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10637-014-0159-5","article-title":"A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin","volume":"32","author":"Brana","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymthe.2024.11.010_bib41","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.jchromb.2011.06.005","article-title":"Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography","volume":"879","author":"Andr\u00e1si","year":"2011","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ymthe.2024.11.010_bib42","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.1999.17.8.2604","article-title":"Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies","volume":"17","author":"Hammond","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-013-2826-1","article-title":"Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care","volume":"143","author":"Jager","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2024.11.010_bib44","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1158\/0008-5472.CAN-06-4095","article-title":"Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species","volume":"67","author":"De Milito","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40360-020-00433-2","article-title":"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole","volume":"21","author":"Ochoa","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-023-02234-z","article-title":"Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I\/II randomized study","volume":"41","author":"Noronha","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib47","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1634\/theoncologist.2018-0621","article-title":"Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","volume":"24","author":"Hansen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2024.11.010_bib48","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00171.2020","article-title":"Explosion in the complexity of membrane protein recycling","volume":"320","author":"McDonald","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/17474124.1.2.197","article-title":"Pantoprazole: a proton pump inhibitor with oral and intravenous formulations","volume":"1","author":"Devault","year":"2007","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2024.11.010_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cpdd.999","article-title":"Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults","volume":"11","author":"Stoll","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymthe.2024.11.010_bib52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00280-020-04074-4","article-title":"A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects","volume":"85","author":"Ogasawara","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11064-020-02964-w","article-title":"Aerobic Glycolysis in the Brain: Warburg and Crabtree Contra Pasteur","volume":"46","author":"Barros","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/bjc.1991.326","article-title":"Are cancer cells acidic?","volume":"64","author":"Griffiths","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.010_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2024.11.010_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib57","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.010_bib58","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/s41388-019-0893-4","article-title":"FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis","volume":"38","author":"Cordero","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2024.11.010_bib59","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib61","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ccell.2021.07.009","article-title":"Tumor heterogeneity","volume":"39","author":"Pe'er","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2024.11.010_bib62","first-page":"F868","article-title":"H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole","volume":"266","author":"Saboli\u0107","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib63","first-page":"23","article-title":"Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in\u00a0vivo","volume":"108","author":"Larsson","year":"1985","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"10.1016\/j.ymthe.2024.11.010_bib64","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1080\/15548627.2022.2125629","article-title":"The Acid Gate in the Lysosome","volume":"19","author":"Hu","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2024.11.010_bib65","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/JCMA.0000000000000785","article-title":"Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors","volume":"85","author":"Lee","year":"2022","journal-title":"J.\u00a0Chin. Med. Assoc."},{"key":"10.1016\/j.ymthe.2024.11.010_bib66","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-017-3298-5","article-title":"Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","volume":"79","author":"Tan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib67","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1479-5876-11-268","article-title":"Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed","volume":"11","author":"Ferrari","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13046-015-0194-x","article-title":"Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer","volume":"34","author":"Wang","year":"2015","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib69","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.dld.2016.08.126","article-title":"High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art","volume":"48","author":"Falcone","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ymthe.2024.11.010_bib70","first-page":"377","article-title":"Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial","volume":"15","author":"Marchetti","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ymthe.2024.11.010_bib71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-019-03251-7","article-title":"Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms","volume":"144","author":"Albatany","year":"2019","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2024.11.010_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13321","article-title":"Proton pump inhibitors display anti-tumour potential in glioma","volume":"56","author":"Li","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ymthe.2024.11.010_bib73","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0149-2918(00)83025-8","article-title":"Pantoprazole: a new proton pump inhibitor","volume":"22","author":"Jungnickel","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib74","first-page":"S31","article-title":"Lack of pantoprazole drug interactions in man: an updated review","volume":"34","author":"Steinijans","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.010_bib75","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib76","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-13-0128","article-title":"Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors","volume":"19","author":"Patel","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T\u00a0cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2024.11.010_bib79","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.11.010_bib80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-024-03042-7","article-title":"Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication","volume":"43","author":"Chen","year":"2024","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.010_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2070337","article-title":"Overcoming T\u00a0cell dysfunction in acidic pH to enhance adoptive T\u00a0cell transfer immunotherapy","volume":"11","author":"Navarro","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.11.010_bib82","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.omto.2020.07.005","article-title":"Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model","volume":"18","author":"Klampatsa","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2024.11.010_bib83","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.11.010_bib84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.11.010_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC bioinformatics"},{"key":"10.1016\/j.ymthe.2024.11.010_bib86","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:29:59Z","timestamp":1783020599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624007378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1525001624007378"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.010","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}